AI-Immunology™ We strive to develop novel drugs with an unprecedented level of efficacy and precision. Using AI, we simulate the human immune system and generate predictive models to identify and develop personalized and other next-generation immunotherapies for patients.
PIONEER™ is a proprietary AI-Immunology™ model for the rapid discovery of patient-specific neoantigens used for our personalized cancer immunotherapies. We want to challenge and improve the standardized therapies of today, where one size fits all, risking unspecific immune activation. With our AI-Immunology™ platform, we seek out and target cancer cells, creating truly personalized therapies where one size fits one and only one.
Related Press Releases
Nov 28, 2023
Evaxion to Unveil Potentially Groundbreaking AI-Immunology™ Precision Cancer Vaccine Concept
Nov 15, 2023
Evaxion Presents Proof-of-Principle for Its Unique AI Model Predicting Responses to Cancer Immunotherapy
Subscribe to our Newsletter
Be the first to know about news, milestones and events at Evaxion by subscribing to our newsletter. You'll only hear from us when it's important, and can unsubscribe at any time.